Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]

  • Awaiting development
  • GID-TA11608
  • Expected publication date: TBC

10242-Imetelstat-for-Myelofibrosis-V1.0-JUN2024-NON-CONF.pdf (nihr.ac.uk)